Medexus Pharmaceuticals Reports Mixed Q1 2025 Results
Company Announcements

Medexus Pharmaceuticals Reports Mixed Q1 2025 Results

Story Highlights

Medexus Pharmaceuticals Inc (TSE:MDP) has released an update.

Medexus Pharmaceuticals Inc. reported a decline in revenue to $27.3 million in fiscal Q1 2025, a 13.6% decrease from the previous year, primarily due to reduced sales of Rasuvo and IXINITY. Despite the revenue drop, the company achieved a net income increase to $2.0 million and maintained a strong Adjusted EBITDA of $6.1 million. These results reflect the company’s continued cost management efforts and revenue from key products like Rupall.

For further insights into TSE:MDP stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Canadian Auto-Generated NewsdeskMedexus Pharmaceuticals Reports Strong Q2 2025 Results
TipRanks Canadian Auto-Generated NewsdeskMedexus Shareholders Show Strong Support at Annual Meeting
TipRanks Canadian Auto-Generated NewsdeskMedexus Awaits FDA Decision on Treosulfan After Delay
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App